WALTHAM, Mass., May 03, 2024--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 551,000 shares of the company’s common stock to six
WALTHAM, Mass., April 29, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, May 8 at 8:00 a.m. ET to discuss its first quarter 2024 financial results and recent business highlights.
WALTHAM, Mass., March 05, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11 at 2:00 p.m. ET.